1618-P: Time Trends of Diabetes Prevalence and Incidence in France: A Nationwide Study

Abstract

Background: Our objective was to assess trends on incidence and prevalence rates of pharmacologically-treated diabetes in France between 2010 and 2016. Methods: Diabetes cases were identified in the National Health Data System (SNDS), covering the whole of France, i.e., 66 million people, through a validated algorithm based on antidiabetic drugs reimbursements. Incident cases were identified as new diabetes cases in people free of diabetes during the 2 previous years. For a given year, mean number of residents in France was used to calculate prevalence and incidence rates. Finally, Poisson models were applied to assess possible effects of age, sex and geographical region on time trends. Results: Prevalence slightly increased from 4.3% in 2010 to 4.9% in 2016, with a significant increasing annual time trend for the period of 1.9% (95% CI: 1.7%-2.1%). After adjustment, the increasing time trend was more important among people under 45 and people over 75 years. In 2012, incidence was 4.2 while in 2016 it was 3.9 cases per 1000 person-years. A non-significant decreasing annual time trend was observed for the period 2012-2016 (-1.3%, 95% CI -2.8%, 0.2%). This decreasing time trend was stronger in adults over 45 years and among women, after adjustment. Conclusion: Between 2010 and 2016, the prevalence of diabetes increased while incidence of diabetes remained stable. Further efforts on diabetes prevention are required. Disclosure S. Fuentes: None. S. Fosse-Edorh: None. P. Bernillon: None. C. Bonaldi: Employee; Spouse/Partner; Novartis France. E. Cosson: Board Member; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., LifeScan, Inc., Lilly Diabetes, Medtronic, Merck Sharp & Dohme Corp., Novartis France, Novo Nordisk A/S, Roche Diagnostics France, Sanofi. Research Support; Self; Air Liquide, Lilly Diabetes, Novo Nordisk A/S, Roche Diagnostics France, Roche Foundation, Sanofi. Funding Santé Public France